Fig. 4
From: RNAi mechanisms in Huntington’s disease therapy: siRNA versus shRNA
Construct design for promoter modulation. Various promoters can be coupled with mHTT variants for alle-specific silencing (and compared to a control such as dRho). An IRES followed by GFP may be used to confirm construct expression. The “special” promoters include the HTT promoter itself, and the PGC1-a promoter which is activated by TFAM when HTT aggregates induce autophagy or lysosome formation